[
  {
    "ts": null,
    "headline": "Davis Opportunity Fund 2025 Semi-Annual Review",
    "summary": "Davis Opportunity Fund returned 9.50% in the first six months of 2025, outperforming its benchmark. Read more here.",
    "url": "https://finnhub.io/api/news?id=c43f682b546edff03d51993ad7be9c63452e6b07c24299515e88d74f14866313",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754951400,
      "headline": "Davis Opportunity Fund 2025 Semi-Annual Review",
      "id": 136313722,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "VTRS",
      "source": "SeekingAlpha",
      "summary": "Davis Opportunity Fund returned 9.50% in the first six months of 2025, outperforming its benchmark. Read more here.",
      "url": "https://finnhub.io/api/news?id=c43f682b546edff03d51993ad7be9c63452e6b07c24299515e88d74f14866313"
    }
  },
  {
    "ts": null,
    "headline": "Tracking Christopher Davis' Davis Selected Advisers 13F Portfolio - Q2 2025 Update",
    "summary": "Tracking Christopher Davis' Davis Selected Advisers 13F Portfolio - Q2 2025 Update",
    "url": "https://finnhub.io/api/news?id=e9dde0be3e9c7edcc68fc9bce5951677a5ebb9247eb1fd21f8fade3db1768f8f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754943475,
      "headline": "Tracking Christopher Davis' Davis Selected Advisers 13F Portfolio - Q2 2025 Update",
      "id": 136313089,
      "image": "",
      "related": "VTRS",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e9dde0be3e9c7edcc68fc9bce5951677a5ebb9247eb1fd21f8fade3db1768f8f"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Rise Late Afternoon",
    "summary": "Health care stocks increased late Monday afternoon, with the NYSE Health Care Index and the Health C",
    "url": "https://finnhub.io/api/news?id=046313e444eb9834a1f94412ad692462858c20c5d7d96dc059a72186fa7804ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754941975,
      "headline": "Sector Update: Health Care Stocks Rise Late Afternoon",
      "id": 136311725,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Health care stocks increased late Monday afternoon, with the NYSE Health Care Index and the Health C",
      "url": "https://finnhub.io/api/news?id=046313e444eb9834a1f94412ad692462858c20c5d7d96dc059a72186fa7804ee"
    }
  },
  {
    "ts": null,
    "headline": "Why Viatris (VTRS) Stock Is Up Today",
    "summary": "Shares of medication company Viatris (NASDAQ:VTRS) jumped 3% in the morning session after it received approval from the U.S. Food and Drug Administration (FDA) for its Iron Sucrose Injection, USP, the first generic version of Venofer速 Injection. The intravenous iron replacement product is used to treat iron deficiency anemia in adult and pediatric patients with chronic kidney disease. This approval marks a significant milestone, as it's the first generic version of Venofer速, a drug with annual U",
    "url": "https://finnhub.io/api/news?id=563027e6a59fa3ba696b6b1b37d5eab7981a1ebd2bd0b5d387d25c878067132d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754929888,
      "headline": "Why Viatris (VTRS) Stock Is Up Today",
      "id": 136311130,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Shares of medication company Viatris (NASDAQ:VTRS) jumped 3% in the morning session after it received approval from the U.S. Food and Drug Administration (FDA) for its Iron Sucrose Injection, USP, the first generic version of Venofer速 Injection. The intravenous iron replacement product is used to treat iron deficiency anemia in adult and pediatric patients with chronic kidney disease. This approval marks a significant milestone, as it's the first generic version of Venofer速, a drug with annual U",
      "url": "https://finnhub.io/api/news?id=563027e6a59fa3ba696b6b1b37d5eab7981a1ebd2bd0b5d387d25c878067132d"
    }
  },
  {
    "ts": null,
    "headline": "Viatris, Amphastar Pharmaceuticals Get FDA Approvals of Iron Sucrose Products",
    "summary": "Viatris, Amphastar Pharmaceuticals Get FDA Approvals of Iron Sucrose Products",
    "url": "https://finnhub.io/api/news?id=1b3e3f595929690e20a7d125b792cc4a8520884c9a839abfc46189c5bf13cdfa",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754921160,
      "headline": "Viatris, Amphastar Pharmaceuticals Get FDA Approvals of Iron Sucrose Products",
      "id": 137154118,
      "image": "",
      "related": "VTRS",
      "source": "MarketWatch",
      "summary": "Viatris, Amphastar Pharmaceuticals Get FDA Approvals of Iron Sucrose Products",
      "url": "https://finnhub.io/api/news?id=1b3e3f595929690e20a7d125b792cc4a8520884c9a839abfc46189c5bf13cdfa"
    }
  },
  {
    "ts": null,
    "headline": "Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.",
    "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the U.S. Food and Drug Administration (FDA) has approved Iron Sucrose Injection, USP, an intravenous iron replacement product used to treat iron deficiency anemia (IDA) in adult and pediatric patients (2 years of age and older) with chronic kidney disease (CKD). IDA is a common complication of CKD and is associated with a significantly heightened risk of cardiovascular morbidity and higher mortality rates. Iron Sucrose Inj",
    "url": "https://finnhub.io/api/news?id=aedee02c9c474e142c659dfa523df11f1fc154481c0969cc963d63d067810adc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754918940,
      "headline": "Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.",
      "id": 136294694,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the U.S. Food and Drug Administration (FDA) has approved Iron Sucrose Injection, USP, an intravenous iron replacement product used to treat iron deficiency anemia (IDA) in adult and pediatric patients (2 years of age and older) with chronic kidney disease (CKD). IDA is a common complication of CKD and is associated with a significantly heightened risk of cardiovascular morbidity and higher mortality rates. Iron Sucrose Inj",
      "url": "https://finnhub.io/api/news?id=aedee02c9c474e142c659dfa523df11f1fc154481c0969cc963d63d067810adc"
    }
  }
]